Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison Between Intravitreal Injection of Ranibizumab and Bevacizumab for Treatment of Type 1 Retinopathy of Prematurity

NCT05033106 is registered in ClinicalTrials.gov with Zagazig University as lead sponsor.

NCT NCT05033106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05033106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison Between Intravitreal Injection of Ranibizumab and Bevacizumab for Treatment of Type 1 Retinopathy of Prematurity
Lead sponsor
Zagazig University
Phase
Phase 3
Overall status
Unknown status
Start date
September 1, 2020
Completion date
September 1, 2022
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinopathy of prematurity both eyes